Tearsheet

Monte Rosa Therapeutics (GLUE)

Market Price (4/10/2026): $18.17 | Market Cap: $1.6 Bil
Sector: Health Care | Industry: Biotechnology

Monte Rosa Therapeutics (GLUE)

Market Price (4/10/2026): $18.17
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.64, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -54 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -44%

Stock price has recently run up significantly
6M Rtn6 month market price return is 113%, 12M Rtn12 month market price return is 345%

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -95%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 271%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6%

Key risks
GLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64%
2	Megatrend and thematic drivers Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.
3	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.64, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -54 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -44%
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 113%, 12M Rtn12 month market price return is 345%
6	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -95%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
8	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22%
9	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 271%
10	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6%
11	Key risks GLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more.

Valuation, Metrics & Events

	4/10/26	2025	2024	2023	2022
Share Price CYE	$18.17	$4.64	$7.05	$7.79	$14.02
Market Cap CYE ($ Bil)	1.6	0.4	0.4	0.4	0.7
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.4	0.3	0.2	0.2	0.3
Enterprise Value ($ Bil)	1.2	0.4	0.4	0.4	0.7
Valuation Ratios
P/S TTM	12.6	2.4	398.6	-	-
P/EBIT TTM	-28.7	-179.0	-2.9	-3.1	-7.6
P/E TTM	-40.2	61.9	-3.1	-3.3	-7.6
P/FCF TTM	-56.5	12.5	-6.1	-3.5	-8.0
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/10/26	2025	2024
Share Price CYE	$18.17	$4.64	$7.05
Market Cap CYE ($ Bil)	1.6	0.4	0.4
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.4	0.3	0.2
Enterprise Value ($ Bil)	1.2	0.4	0.4
Valuation Ratios
P/S TTM	12.6	2.4	398.6
P/EBIT TTM	-28.7	-179.0	-2.9
P/E TTM	-40.2	61.9	-3.1
P/FCF TTM	-56.5	12.5	-6.1
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	GLUE	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.1
Rev Chg Q	-95.4%	7.4%
Rev Chg LTM	63.5%	6.8%
Rev Chg 3Y Avg	63.5%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-43.8%	18.6%
CFO/Rev LTM	-18.4%	20.7%
Net Inc Mgn	-31.2%	12.8%
VALUATION	VERY HIGH
P/S	12.6	3.3
P/CFO	-68.2	15.6
P/FCF	-56.5	20.2
P/E	-40.2	24.3
STABILITY	VERY GOOD
Debt/Equity	0.03	0.21
Cash/Assets	0.84	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Clinical Programs	3	11062025	Link
Number of Wholly-Owned Pipeline INDs Anticipated in Next 2 Years	Multiple	11062025	Link
Potential Milestone Payments from Novartis VAV1 Collaboration	up to $2.1 billion	11062025	Link
Potential Milestone Payments from Novartis Immune-Mediated Diseases Collaboration	up to $5.7 billion	11062025	Link
Potential Milestone Payments from Roche Collaboration	>$2 billion	11062025	Link
Number of Patients to be Enrolled in MRT-2359 mCRPC Updated Clinical Results	20 to 30	11062025	Link

Recent
3/17/2026	Earnings Release	Rev: $2.0 Mil (A) vs. $15 Mil (E) EPS: -0.54 (A) vs. $-0.35 (E)
Upcoming
5/14/2026	Earnings Release	Rev: $13 Mil (E) EPS: $-0.36 (E)

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Monte Rosa Therapeutics (GLUE) stock has gained about 15% since 12/31/2025 because of the following key factors:

1. Positive Interim Clinical Data for MRT-8102 Driven by Significant CRP Reductions.

Monte Rosa Therapeutics announced positive interim Phase 1 clinical study results for its NEK7-directed molecular glue degrader, MRT-8102, on January 7, 2026. The data demonstrated rapid and durable reductions in systemic inflammation, with an 85% decrease in C-reactive protein (CRP) levels after four weeks of treatment in subjects with elevated cardiovascular disease risk. Additionally, 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease risk. This positive clinical update spurred a significant surge in the stock, including a 42.66% rise in pre-market trading on January 7, 2026.

2. Promising Clinical Activity of MRT-2359 and Strategic Collaboration for Prostate Cancer.

Further positive clinical updates contributed to the stock's trend, particularly for MRT-2359, a molecular glue degrader targeting metastatic castration-resistant prostate cancer (mCRPC). In February and March 2026, Monte Rosa presented updated interim data from its Phase 1/2 study, showing a 100% PSA response rate in a five-patient subset with AR-mutant mCRPC when MRT-2359 was combined with enzalutamide. On March 16, 2026, the company announced a clinical supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with apalutamide, with plans to initiate a Phase 2 study in Q3 2026.

Show more

Stock Movement Drivers

Fundamental Drivers

The 15.1% change in GLUE stock from 12/31/2025 to 4/9/2026 was primarily driven by a 75.4% change in the company's P/S Multiple.

(LTM values as of)	12312025	4092026	Change
Stock Price ($)	15.68	18.05	15.1%
Change Contribution By:
Total Revenues ($ Mil)	182	124	-31.9%
P/S Multiple	7.1	12.5	75.4%
Shares Outstanding (Mil)	82	86	-3.7%
Cumulative Contribution			15.1%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/9/2026

	Return	Correlation
GLUE	15.1%
Market (SPY)	-5.4%	3.5%
Sector (XLV)	-3.5%	23.5%

Fundamental Drivers

The 143.6% change in GLUE stock from 9/30/2025 to 4/9/2026 was primarily driven by a 264.9% change in the company's P/S Multiple.

(LTM values as of)	9302025	4092026	Change
Stock Price ($)	7.41	18.05	143.6%
Change Contribution By:
Total Revenues ($ Mil)	178	124	-30.5%
P/S Multiple	3.4	12.5	264.9%
Shares Outstanding (Mil)	82	86	-3.9%
Cumulative Contribution			143.6%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/9/2026

	Return	Correlation
GLUE	143.6%
Market (SPY)	-2.9%	9.8%
Sector (XLV)	7.8%	13.8%

Fundamental Drivers

The 289.0% change in GLUE stock from 3/31/2025 to 4/9/2026 was primarily driven by a 147.8% change in the company's P/S Multiple.

(LTM values as of)	3312025	4092026	Change
Stock Price ($)	4.64	18.05	289.0%
Change Contribution By:
Total Revenues ($ Mil)	76	124	63.5%
P/S Multiple	5.0	12.5	147.8%
Shares Outstanding (Mil)	82	86	-4.0%
Cumulative Contribution			289.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/9/2026

	Return	Correlation
GLUE	289.0%
Market (SPY)	16.3%	17.0%
Sector (XLV)	3.7%	20.2%

Fundamental Drivers

The 131.7% change in GLUE stock from 3/31/2023 to 4/9/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4092026	Change
Stock Price ($)	7.79	18.05	131.7%
Change Contribution By:
Total Revenues ($ Mil)	0	124	9.2233720368547763E17%
P/S Multiple	∞	12.5
Shares Outstanding (Mil)	49	86	-42.8%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/9/2026

	Return	Correlation
GLUE	131.7%
Market (SPY)	63.3%	20.1%
Sector (XLV)	20.8%	18.8%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
GLUE Return	-4%	-63%	-26%	23%	126%	9%	-19%
Peers Return	-3%	-49%	-3%	13%	2%	11%	-38%
S&P 500 Return	27%	-19%	24%	23%	16%	-1%	81%
Monthly Win Rates [3]
GLUE Win Rate	71%	33%	33%	50%	50%	50%
Peers Win Rate	52%	43%	35%	48%	55%	45%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
GLUE Max Drawdown	-23%	-70%	-67%	-40%	-47%	-8%
Peers Max Drawdown	-27%	-59%	-57%	-30%	-53%	-12%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, NRIX, ARVN, CCCC, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/9/2026 (YTD)

How Low Can It Go

Unique Key	Event	GLUE	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-94.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1588.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to KYMR, NRIX, ARVN, CCCC, BMY

In The Past

Monte Rosa Therapeutics's stock fell -94.1% during the 2022 Inflation Shock from a high on 9/3/2021. A -94.1% loss requires a 1588.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Monte Rosa Therapeutics (GLUE)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

AI Analysis | Feedback

Genentech for targeted protein degradation.
Moderna for protein 'clean-up' drugs.

AI Analysis | Feedback

Oral molecular glue degrader for GSPT1: A precision medicine for the treatment of Myc-driven cancers.
CDK2: A treatment in development for ovarian, uterine, and breast cancers.
NEK7: A therapeutic target for inflammatory diseases, including Crohn's disease, neurodegenerative disease, diabetes, and liver disease.
VAV1: A target protein being developed for autoimmune diseases.
BCL11A: A therapeutically-relevant protein targeted for hemoglobinopathies.

AI Analysis | Feedback

Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biopharmaceutical company focused on the research and development of novel small molecule precision medicines. As of now, the company does not have any commercialized products on the market.

Therefore, Monte Rosa Therapeutics does not currently have major customers that purchase its products. Its primary activities are advancing its pipeline candidates through preclinical and clinical development.

AI Analysis | Feedback

null

AI Analysis | Feedback

Markus Warmuth, M.D., Chief Executive Officer

Dr. Warmuth has served as President and Chief Executive Officer of Monte Rosa Therapeutics since January 2020. He brings over 20 years of experience in drug discovery and precision medicine. Prior to Monte Rosa, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he was involved in forming new biotech companies. He also served as Chief Executive Officer of H3 Biomedicine for seven years, an oncology biopharmaceutical company, leading teams involved in developing Ceritinib and Ribociclib. Dr. Warmuth also held multiple leadership roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), contributing to the development of Ceritinib and Ribociclib, and the discovery of allosteric SHP2 and Abl inhibitors. He currently serves as a Venture Partner at Versant Ventures.

Ajim Tamboli, CFA, Chief Financial Officer

Mr. Tamboli has served as Chief Financial Officer of Monte Rosa Therapeutics since September 2020. He was instrumental in leading private and public fundraises exceeding $465 million for Monte Rosa, including an upsized $255 million IPO. Before joining Monte Rosa, Mr. Tamboli was CFO at Rodin Therapeutics, where he managed investor fundraising and supported its acquisition by Alkermes for up to $950 million. He also previously served as a founding partner of Endurant Capital Management, a healthcare-dedicated asset management firm, and worked with Columbia Management, focusing on life sciences investing and managing a global portfolio of biotech and pharmaceutical companies. Earlier in his career, he led coverage and executed IPOs and follow-on offerings for numerous biotech and healthcare companies at Lehman Brothers, Credit Suisse, and Lazard Frères.

Sharon Townson, Ph.D., Chief Scientific Officer

Dr. Townson was promoted to Chief Scientific Officer on May 30, 2024, after joining Monte Rosa as Chief Technology Officer. She brings extensive expertise in molecular glues and targeted protein degradation technology platforms. Prior to Monte Rosa, she served as Executive Director of Platform Biology at Kymera Therapeutics. Dr. Townson was also part of the leadership team at Warp Drive Bio, where she was responsible for developing a novel molecular glue approach targeting KRAS. She began her career at Pfizer as a structural biologist.

Jennifer Champoux, Chief Operating Officer

Ms. Champoux was promoted to Chief Operating Officer on May 30, 2024. She previously held the roles of Chief People and Operations Officer since March 2023 and Senior Vice President of Operations from March 2021 to March 2023 at Monte Rosa. Before joining the company, Ms. Champoux was Executive Director of Operations at H3 Biomedicine, leading operations, communications, and finance operations teams. She also led operations for the Discovery Chemistry group at Novartis Institutes for Biomedical Research in Cambridge. Her career began in various pharmaceutical development functions at Merck and Array BioPharma.

Phil Nickson, Ph.D., J.D., Chief Business and Legal Officer

Dr. Nickson was promoted to Chief Business and Legal Officer on May 30, 2024, having joined Monte Rosa in 2021 as General Counsel to support the company's IPO. In his role, he leads Monte Rosa's business development and legal departments. Prior to Monte Rosa, he spent over 10 years with Momenta Pharmaceuticals until its acquisition by Johnson and Johnson in 2020, and then supported the integration of Momenta into J&J for approximately one year.

AI Analysis | Feedback

Key Risks to Monte Rosa Therapeutics (GLUE)

Clinical Trial Success and Development Risk: As an early-stage biopharmaceutical company, Monte Rosa Therapeutics' business heavily relies on the successful development and clinical validation of its novel small molecule precision medicines. The inherent failure rates in clinical trials are high, and the success of its drug candidates, currently in Phase 1 and progressing to Phase 2, is the primary and highest-impact catalyst for the company. Biopharmaceutical drug development is a highly speculative undertaking with a substantial degree of risk.
Funding, Cash Burn, and Shareholder Dilution Risk: Developing new drugs is an expensive and capital-intensive process. Monte Rosa Therapeutics has a significant cash burn and, as an early-stage biotech, will likely require future financing, which poses a substantial risk of dilution for existing shareholders. Despite a current cash runway expected to last into 2028, recent equity raises have already highlighted concerns about potential dilution. The company has also experienced unstable profits and declining revenue forecasts.
Regulatory Approval and Unproven Technology Risk: Even with successful clinical trials, obtaining regulatory approval (e.g., from the FDA) for its drug candidates is not guaranteed and can be unpredictable, potentially hindering market entry and future opportunities. Furthermore, Monte Rosa's core molecular glue degrader technology, while innovative and promising, is still largely unproven in its broader application and commercialization, introducing an additional layer of uncertainty regarding its long-term viability and competitive standing.

AI Analysis | Feedback

null

AI Analysis | Feedback

Monte Rosa Therapeutics (symbol: GLUE) is developing precision medicines targeting various diseases. The addressable markets for their main product candidates are outlined below.

Oral molecular glue degrader for GSPT1 (Myc-driven cancers): The global Myc proto-oncogene protein market was valued at USD 1.68 billion in 2024 and is projected to grow to USD 3.06 billion by 2029. The GSPT1 segment of the global molecular glue degrader market was estimated at approximately USD 74.3 million in 2024.
CDK2 inhibitor (Ovarian, Uterine, and Breast Cancers):
- Ovarian Cancer: The global ovarian cancer treatment market size was estimated at USD 3.5 billion in 2023, with projections to reach approximately USD 6.5 billion by 2032. The global ovarian cancer drugs market size was USD 4.09 billion in 2025 and is projected to hit around USD 7.78 billion by 2035.
- Uterine Cancer: The global uterine cancer treatment market size was approximately USD 23,633.46 million (USD 23.63 billion) in 2024 and is expected to reach nearly USD 39,007.22 million (USD 39.01 billion) by 2033.
- Breast Cancer: The global breast cancer market size was estimated at USD 26.23 billion in 2025 and is predicted to increase to approximately USD 40.11 billion by 2035.
NEK7 inhibitor (Inflammatory Diseases, such as Crohn's disease, Neurodegenerative disease, Diabetes, and Liver disease):
- Crohn's Disease: The global Crohn's Disease Market was estimated at USD 11.93 billion in 2024 and is projected to grow to USD 17.83 billion by 2035.
- Neurodegenerative Disease: The global neurodegenerative disease market size is estimated to be valued at USD 55.6 billion in 2025 and is projected to reach USD 109.5 billion by 2035.
- Diabetes: The global diabetes drugs market size was valued at USD 101.48 billion in 2025 and is projected to grow to USD 283.36 billion by 2034.
- Liver Disease: A specific addressable market size for "inflammatory liver disease" was not identified in the provided search results.
VAV1 (Autoimmune Diseases): The global autoimmune disease therapeutics market is valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035.
BCL11A (Hemoglobinopathies): The global hemoglobinopathies market size is valued at USD 5.12 billion in 2025 and is predicted to increase to approximately USD 8.87 billion by 2035.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Monte Rosa Therapeutics (GLUE) over the next 2-3 years:

Milestone Payments from Novartis Collaboration for MRT-6160: Monte Rosa Therapeutics is eligible to receive significant development, regulatory, and sales milestones, potentially up to $2.1 billion, from its collaboration with Novartis for the VAV1-directed molecular glue degrader (MGD) MRT-6160. These payments are expected to begin upon the initiation of Phase 2 studies, which Novartis is anticipated to commence for MRT-6160 in immune-mediated diseases in 2026.
Advancement of MRT-2359 into Phase 2 Studies: The company plans to initiate a Phase 2 study in the third quarter of 2026 for MRT-2359, its GSPT1 degrader, in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC). This progression into a later-stage clinical trial, following encouraging Phase 1/2 data, is a key clinical catalyst that could drive future revenue.
Progression of MRT-8102 into Phase 2 Studies: Monte Rosa Therapeutics expects to share data from its GFORCE-1 study of MRT-8102, a NEK7-directed MGD for inflammatory diseases, in the second half of 2026. This is expected to lead to the initiation of the Phase 2 GFORCE-2 study in atherosclerotic cardiovascular disease (ASCVD) in 2026. Positive interim Phase 1 data showing robust activity and reduction in inflammatory markers supports this advancement.
Initiation of New Clinical Programs from the QuEEN™ Discovery Engine: Leveraging its proprietary QuEEN™ AI/ML-powered discovery engine, Monte Rosa Therapeutics anticipates submitting an Investigational New Drug (IND) application in 2026 for a CDK2 and/or cyclin E1-directed MGD. This would introduce a new oncology program into clinical development, expanding the company's pipeline and future revenue potential.

AI Analysis | Feedback

Share Issuance

Monte Rosa Therapeutics completed its Initial Public Offering (IPO) on June 24, 2021, issuing 11,700,000 shares of common stock at $19.00 per share and receiving net proceeds of $203.9 million after deducting underwriting discounts and offering costs.
The company terminated its at-the-market (ATM) equity program prospectus on January 7, 2026, after raising $24.2 million through this program.
The number of outstanding shares for Monte Rosa Therapeutics increased by 22.34% in the year prior to March 2026.

Inbound Investments

Monte Rosa Therapeutics reported collaboration revenue of $12.8 million in Q3 2025, up from $9.2 million a year prior.
The company recorded net income of $7.5 million year-to-date in Q3 2025, reflecting collaboration activity, including the completion of a $150.0 million upfront payment under a 2024 Novartis license.
In October 2023, Monte Rosa Therapeutics AG, a wholly-owned subsidiary, entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).

Capital Expenditures

Monte Rosa Therapeutics, Inc. invested $651,000 in capital expenditures in Q3 2025, a 61.6% decrease from the previous quarter.
For the last 12 months (ending around Q3 2025), capital expenditures were -$4.12 million.
The company expects its capital expenditures to continue increasing.

Interactive Breakdown

null

null

Better Bets vs. Monte Rosa Therapeutics (GLUE)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102	01/07/2026
2	Monte Rosa Therapeutics Earnings Notes	12/16/2025
3	Is Monte Rosa Therapeutics Stock Built to Withstand a Pullback?	10/17/2025
4	Day 6 of Gains Streak for Monte Rosa Therapeutics Stock with 51% Return (vs. 60% YTD) [10/15/2025]	10/16/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to GLUE.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
EOSE	Eos Energy Enterprises	1.8	29.6%	-48.1%
YSS	York Space Systems	4.5	28.8%	7.1%
MPLT	MapLight Therapeutics	1.2	21.3%	67.4%
STAA	Staar Surgical	1.3	20.7%	9.2%
AXTI	AXT	2.8	18.7%	286.1%
FNMA	Federal National Mortgage Association Fannie Mae	46.1	18.6%	-26.7%
OGN	Organon	1.8	17.9%	-3.4%
FMCC	Federal Home Loan Mortgage	22.5	17.6%	-31.5%
IOVA	Iovance Biotherapeutics	1.6	15.6%	46.9%
ORIC	ORIC Pharmaceuticals	1.1	14.7%	26.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
SMPL	Simply Good Foods	1.2	-18.1%	-41.2%
TPL	Texas Pacific Land	26.1	-15.7%	31.7%
QLYS	Qualys	2.7	-12.2%	-42.3%
SNOW	Snowflake	45.3	-11.8%	-39.7%
ZS	Zscaler	19.5	-11.3%	-45.7%
OKTA	Okta	12.0	-10.9%	-21.6%
SAIL	SailPoint	6.2	-10.9%	-45.3%
RBRK	Rubrik	9.3	-10.6%	-39.6%
BLLN	BillionToOne	3.8	-10.3%	0.8%
AXON	Axon Enterprise	27.8	-10.3%	-38.1%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
CAR	Avis Budget	10.5	74.7%	131.5%
AEHR	Aehr Test Systems	2.1	73.9%	241.1%
AAOI	Applied Optoelectronics	9.4	54.4%	282.4%
YSS	York Space Systems	4.5	52.6%	7.1%
SLNO	Soleno Therapeutics	2.8	42.0%	13.4%
MPLT	MapLight Therapeutics	1.2	41.2%	67.4%
RLAY	Relay Therapeutics	2.6	39.3%	77.3%
ORIC	ORIC Pharmaceuticals	1.1	38.9%	26.9%
HUT	Hut 8	6.9	33.9%	38.0%
AXTI	AXT	2.8	33.9%	286.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.5	-22.3%	-39.2%
TBN	Tamboran Resources	0.7	-21.4%	29.8%
GEVO	Gevo	0.5	-20.3%	-4.5%
VRDN	Viridian Therapeutics	1.5	-19.7%	-50.6%
SEDG	SolarEdge Technologies	2.5	-19.3%	45.0%
ENPH	Enphase Energy	4.1	-18.3%	-2.5%
RYAM	Rayonier Advanced Materials	0.6	-17.8%	55.5%
SAIL	SailPoint	6.2	-17.2%	-45.3%
AXON	Axon Enterprise	27.8	-17.1%	-38.1%
SMPL	Simply Good Foods	1.2	-16.9%	-41.2%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1428.6%	-4.5%
CAR	Avis Budget	10.5	210.1%	131.5%
SATL	Satellogic	0.9	132.3%	285.0%
APLS	Apellis Pharmaceuticals	5.1	107.0%	61.8%
FLY	Firefly Aerospace	6.0	93.8%	67.9%
LWLG	Lightwave Logic	1.1	93.6%	160.5%
ORKA	Oruka Therapeutics	3.4	88.8%	109.8%
TH	Target Hospitality	1.5	86.7%	86.0%
KODK	Eastman Kodak	1.2	76.7%	45.2%
FBYD	Falcons Beyond Global	0.4	73.4%	-27.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-47.9%	-57.9%
TE	T1 Energy	0.7	-47.6%	-37.4%
VRDN	Viridian Therapeutics	1.5	-47.3%	-50.6%
BUR	Burford Capital	1.0	-46.9%	-50.7%
MAZE	Maze Therapeutics	1.3	-45.4%	-32.7%
FRMI	Fermi	2.9	-40.1%	-39.8%
ADMA	ADMA Biologics	2.4	-37.2%	-45.5%
BOBS	Bobs Discount Furniture	1.5	-36.6%	-32.7%
LMRI	Lumexa Imaging	0.9	-35.6%	-49.7%
AXON	Axon Enterprise	27.8	-33.7%	-38.1%

Peer Comparisons

Peers to compare with:

Financials

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Mkt Price	18.05	87.35	16.24	11.17	2.83	59.47	17.14
Mkt Cap	1.5	7.9	1.8	0.7	0.3	121.0	1.7
Rev LTM	124	39	72	263	36	48,195	98
Op Inc LTM	-54	-346	-315	-118	-104	13,723	-111
FCF LTM	-27	-234	-272	-276	-99	12,845	-167
FCF 3Y Avg	-17	-193	-186	-296	-91	13,146	-138
CFO LTM	-23	-233	-260	-274	-99	14,156	-166
CFO 3Y Avg	-8	-177	-176	-294	-90	14,402	-133

Growth & Margins

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Rev Chg LTM	63.5%	-16.7%	27.2%	-0.3%	1.0%	-0.2%	0.4%
Rev Chg 3Y Avg	-	3.7%	30.3%	65.0%	13.1%	1.5%	13.1%
Rev Chg Q	-95.4%	-61.2%	-66.1%	-84.0%	112.8%	1.3%	-63.7%
QoQ Delta Rev Chg LTM	-31.9%	-10.3%	-14.5%	-15.9%	19.4%	0.3%	-12.4%
Op Mgn LTM	-43.8%	-881.3%	-439.3%	-45.1%	-290.7%	28.5%	-167.9%
Op Mgn 3Y Avg	-	-545.7%	-347.5%	-217.2%	-429.9%	19.6%	-347.5%
QoQ Delta Op Mgn LTM	-48.5%	-130.4%	-99.1%	-12.4%	104.7%	4.7%	-30.5%
CFO/Rev LTM	-18.4%	-594.0%	-362.6%	-104.3%	-274.6%	29.4%	-189.4%
CFO/Rev 3Y Avg	-	-379.3%	-265.0%	-215.3%	-324.1%	30.5%	-265.0%
FCF/Rev LTM	-22.2%	-597.7%	-378.7%	-105.0%	-275.7%	26.7%	-190.4%
FCF/Rev 3Y Avg	-	-404.4%	-279.9%	-217.0%	-327.3%	27.9%	-279.9%

Valuation

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Mkt Cap	1.5	7.9	1.8	0.7	0.3	121.0	1.7
P/S	12.5	200.5	24.9	2.8	9.2	2.5	10.9
P/EBIT	-28.5	-25.3	-5.7	-6.1	-3.2	10.8	-5.9
P/E	-40.0	-25.3	-6.1	-9.0	-3.2	17.1	-7.5
P/CFO	-67.7	-33.8	-6.9	-2.6	-3.4	8.5	-5.1
Total Yield	-2.5%	-4.0%	-16.5%	-11.1%	-31.7%	10.0%	-7.6%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	0.0%
FCF Yield 3Y Avg	-5.0%	-6.3%	-15.5%	-22.9%	-35.8%	12.0%	-10.9%
D/E	0.0	0.0	0.0	0.0	0.2	0.4	0.0
Net D/E	-0.2	-0.1	-0.3	-0.9	-0.6	0.3	-0.2

Returns

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
1M Rtn	4.5%	3.3%	2.1%	-19.2%	-9.3%	-0.1%	1.0%
3M Rtn	-28.7%	16.5%	-12.8%	-8.3%	29.2%	7.5%	-0.4%
6M Rtn	113.4%	53.2%	49.5%	16.5%	17.4%	36.1%	42.8%
12M Rtn	344.6%	264.7%	69.2%	66.0%	117.7%	16.2%	93.4%
3Y Rtn	121.2%	180.4%	81.9%	-59.6%	-9.3%	-2.8%	39.5%
1M Excs Rtn	3.8%	2.6%	1.5%	-19.9%	-9.9%	-0.7%	0.4%
3M Excs Rtn	-21.1%	15.3%	-10.8%	-8.6%	28.9%	7.3%	-0.6%
6M Excs Rtn	142.9%	51.8%	63.6%	18.5%	23.6%	34.5%	43.2%
12M Excs Rtn	310.3%	262.1%	32.3%	40.5%	78.0%	-21.7%	59.3%
3Y Excs Rtn	49.4%	128.7%	17.8%	-126.3%	-77.0%	-66.6%	-24.4%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	3/17/2026	3/17/2026	3/20/2025	3/14/2024	3/16/2023	3/29/2022	6/21/2021
Key Financials
Total Revenue	124	124	76	0	0	0	0
EBITDA	-46	-46	-73	-137	-109	-71	-27
Operating Income	-54	-54	-81	-143	-112	-73	-28
Net Income	-39	-39	-73	-135	-109	-74	-36
EPS	-0.61	-0.46	-0.98	-2.63	-2.30	-2.96	-1.65
Growth Rates
Total Revenue Growth	63.5%	63.5%	∞%	-	-	-	-
EBITDA Growth	37.2%	37.2%	46.8%	-26.2%	-53.6%	-157.5%	-258.3%
Operating Income Growth	33.2%	33.2%	43.4%	-27.5%	-54.2%	-160.2%	-250.4%
Net Income Growth	46.9%	46.9%	46.3%	-24.7%	-46.7%	-106.1%	-363.6%
Margins
EBITDA Margin	-37.1%	-37.1%	-96.5%	-	-	-	-
Operating Income Margin	-43.8%	-43.8%	-107.3%	-	-	-	-
Net Income Margin	-31.2%	-31.2%	-96.1%	-	-	-	-
Cash & Debt
Total Cash	377	377	372	232	263	346	42
Total Debt	39	39	43	46	47	0	0
Net Debt / (Cash)	-338	-338	-329	-186	-216	-346	-42
Cash Flows
Net Cash from Operations	-23	-23	42	-44	-92	-59	-23
Free Cash from Operations	-27	-27	38	-63	-105	-69	-26
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	0	0	1	0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	3/17/2026	11/6/2025	8/7/2025	5/8/2025	3/20/2025	11/7/2024	8/8/2024	5/9/2024	3/14/2024	11/9/2023	8/10/2023	5/11/2023
Key Financials Quarterly
Total Revenue	3	13	23	85	61	9	5	1	0	0	0	0
Ebitda	-48	-31	-13	46	15	-24	-31	-33	-33	-35	-36	-33
Operating Income	-50	-33	-16	44	13	-27	-33	-35	-35	-37	-37	-34
Net Income	-46	-27	-12	47	13	-24	-30	-32	-33	-35	-35	-32
EPS	-0.70	-0.33	-0.15	0.57	0.22	-0.29	-0.43	-0.53	-0.58	-0.70	-0.71	-0.65
Key Financials TTM
Total Revenue TTM	124	182	178	159	76	15	6	1	0	0	0	0
Ebitda TTM	-46	17	23	6	-73	-121	-132	-137	-137	-135	-128	-118
Operating Income TTM	-54	9	15	-2	-81	-129	-139	-144	-143	-141	-132	-122
Net Income TTM	-39	21	24	6	-73	-119	-130	-135	-135	-133	-125	-117
Growth Rates Quarterly
Total Revenue Growth	-95.4%	38.5%	394.0%	7882.0%	-	-	-	-	-	-	-	-
EBITDA Growth	-416.1%	-26.4%	56.1%	239.4%	145.6%	30.5%	14.6%	0.2%	-5.1%	-28.6%	-36.0%	-40.6%
Operating Income Growth	-482.3%	-24.3%	52.3%	226.0%	137.3%	28.2%	12.3%	-2.0%	-7.3%	-30.3%	-36.7%	-41.0%
Net Income Growth	-443.3%	-13.5%	59.4%	246.7%	140.4%	31.6%	13.8%	0.2%	-8.0%	-27.7%	-32.9%	-33.9%
Margins Quarterly
EBITDA Margin	-1712.6%	-241.9%	-57.9%	54.3%	24.8%	-265.0%	-651.4%	-3106.2%	-	-	-	-
Operating Income Margin	-1787.7%	-258.3%	-67.1%	51.9%	21.4%	-287.8%	-695.3%	-3284.5%	-	-	-	-
Net Income Margin	-1658.9%	-212.1%	-53.0%	55.2%	22.2%	-258.9%	-645.6%	-3004.5%	-	-	-	-
Cash & Debt
Total Cash	377	391	291	326	372	242	262	193	232	178	203	232
Total Debt	39	40	41	42	43	44	44	45	46	46	47	46
Net Debt / (Cash)	-338	-351	-249	-284	-329	-198	-218	-148	-186	-132	-156	-186
Cash Flows Quarterly
FCF from Operations	-43	100	-35	-45	129	-21	-28	-38	30	-25	-25	-23
Cash Flows TTM
FCF from Operations TTM	-23	149	28	35	42	-57	-61	-59	-44	-97	-93	-88
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-0	-0	-0	-0	-0	-0	-0	0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-53.4%	-36.2%	-14.7%	45.2%	13.5%	-23.1%	-30.0%	-34.7%	-38.8%	-38.4%	-41.9%	-42.7%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-14.2%	2.5%	3.0%	-0.4%	-24.4%	-28.1%	-32.1%	-35.8%	-39.9%	-36.6%	-37.2%	-38.1%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)	76	0
Total	76	0

Operating Income by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)		-143
Total		-143

Net Income by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)	-73	-135
Total	-73	-135

Assets by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)			342	366
Total			342	366

Price Behavior

Price Behavior

Market Price	$18.05
Market Cap ($ Bil)	1.5
First Trading Date	06/24/2021
Distance from 52W High	-28.7%
	50 Days	200 Days
DMA Price	$17.84	$12.47
DMA Trend	up	down
Distance from DMA	1.2%	44.7%
	3M	1YR
Volatility	50.3%	95.4%
Downside Capture	0.71	0.39
Upside Capture	-48.40	234.84
Correlation (SPY)	13.2%	15.4%

GLUE Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.55	1.09	0.34	0.77	0.85	1.46
Up Beta	-3.60	0.09	0.39	3.54	0.81	1.32
Down Beta	0.88	0.68	1.76	-0.50	0.29	0.92
Up Capture	218%	49%	-28%	241%	309%	808%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	7	15	24	62	123	360
Down Capture	196%	187%	-10%	-13%	88%	111%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	15	27	39	64	127	380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	326.1%	95.2%	1.91	-
Sector ETF (XLV)	12.6%	16.8%	0.54	21.0%
Equity (SPY)	29.1%	17.4%	1.36	15.7%
Gold (GLD)	61.3%	27.8%	1.72	2.8%
Commodities (DBC)	26.9%	16.7%	1.41	-0.1%
Real Estate (VNQ)	17.7%	15.4%	0.86	10.4%
Bitcoin (BTCUSD)	-10.9%	43.9%	-0.14	8.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	-4.1%	102.6%	0.39	-
Sector ETF (XLV)	6.7%	14.6%	0.28	24.2%
Equity (SPY)	11.4%	17.0%	0.52	27.3%
Gold (GLD)	22.2%	17.8%	1.02	4.3%
Commodities (DBC)	11.5%	18.8%	0.50	-1.1%
Real Estate (VNQ)	3.7%	18.8%	0.10	23.6%
Bitcoin (BTCUSD)	3.6%	56.5%	0.29	17.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	-2.1%	102.6%	0.39	-
Sector ETF (XLV)	10.0%	16.5%	0.50	24.2%
Equity (SPY)	13.9%	17.9%	0.67	27.3%
Gold (GLD)	14.1%	15.9%	0.74	4.3%
Commodities (DBC)	8.5%	17.6%	0.40	-1.1%
Real Estate (VNQ)	5.1%	20.7%	0.21	23.6%
Bitcoin (BTCUSD)	67.1%	66.9%	1.06	17.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3132026
Short Interest: Shares Quantity	11.0 Mil
Short Interest: % Change Since 2282026	8.4%
Average Daily Volume	0.9 Mil
Days-to-Cover Short Interest	12.6 days
Basic Shares Quantity	85.5 Mil
Short % of Basic Shares	12.8%

Returns Analyses

	Title
0	Is Monte Rosa Therapeutics Stock Built to Withstand a Pullback?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
3/17/2026	-2.0%	-8.1%
11/6/2025	5.7%	15.0%	45.0%
8/7/2025	-2.9%	2.0%	13.4%
3/20/2025	5.4%	-18.1%	-32.1%
11/7/2024	0.8%	-8.7%	-0.4%
5/9/2024	-1.5%	-0.6%	-24.3%
11/9/2023	-10.6%	-0.3%	17.3%
8/10/2023	-1.6%	-4.7%	-12.1%
...
SUMMARY STATS
# Positive	8	7	8
# Negative	6	7	5
Median Positive	5.3%	7.2%	9.9%
Median Negative	-2.4%	-8.1%	-24.3%
Max Positive	16.3%	37.5%	45.0%
Max Negative	-10.6%	-18.1%	-32.1%

	Forward Returns
3/17/2026	-2.0%	-8.1%
11/6/2025	5.7%	15.0%	45.0%
8/7/2025	-2.9%	2.0%	13.4%
3/20/2025	5.4%	-18.1%	-32.1%
11/7/2024	0.8%	-8.7%	-0.4%
5/9/2024	-1.5%	-0.6%	-24.3%
11/9/2023	-10.6%	-0.3%	17.3%
8/10/2023	-1.6%	-4.7%	-12.1%
3/16/2023	7.4%	7.2%	4.9%
11/10/2022	5.3%	21.8%	12.9%
8/11/2022	5.2%	3.6%	4.0%
3/29/2022	16.3%	37.5%	7.0%
11/12/2021	2.3%	-13.8%	-28.3%
8/12/2021	-3.9%	0.4%	4.1%
SUMMARY STATS
# Positive	8	7	8
# Negative	6	7	5
Median Positive	5.3%	7.2%	9.9%
Median Negative	-2.4%	-8.1%	-24.3%
Max Positive	16.3%	37.5%	45.0%
Max Negative	-10.6%	-18.1%	-32.1%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	03/17/2026	10-K
09/30/2025	11/06/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/08/2025	10-Q
12/31/2024	03/20/2025	10-K
09/30/2024	11/07/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	03/14/2024	10-K
09/30/2023	11/09/2023	10-Q
06/30/2023	08/10/2023	10-Q
03/31/2023	05/11/2023	10-Q
12/31/2022	03/16/2023	10-K
09/30/2022	11/10/2022	10-Q
06/30/2022	08/11/2022	10-Q
03/31/2022	05/11/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 3/17/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2029 Cash Runway						Raised	Guidance: 2,028 for 2028

Prior: Q3 2025 Earnings Reported 11/6/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2028 Cash Runway		2,028		0		Affirmed	Guidance: 2,028 for 2028

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Nickson, Philip	Chief Business & Legal Officer	Direct	Sell	1052026	15.17	3,155	47,861	923,019	Form
2	Champoux, Jennifer	Chief Operating Officer	Direct	Sell	1052026	15.17	2,629	39,882	946,168	Form
3	Dunn, Edmund	Principal Accounting Officer	Direct	Sell	1052026	15.17	1,039	15,762	344,253	Form
4	Warmuth, Markus	President & CEO	Direct	Sell	1052026	15.17	10,135	153,748	9,472,194	Form
5	Janku, Filip	Chief Medical Officer	Direct	Sell	1052026	15.17	3,155	47,861	1,138,144	Form

GLUE Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing GLUE?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What GLUE Makes & Who Pays

TTM figures based on

GLUE Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Monte Rosa Therapeutics (GLUE)

Market Price (4/10/2026): $18.17 | Market Cap: $1.6 BilSector: Health Care | Industry: Biotechnology

Monte Rosa Therapeutics (GLUE)

Market Price (4/10/2026): $18.17Market Cap: $1.6 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Monte Rosa Therapeutics (GLUE)

Key Risks to Monte Rosa Therapeutics (GLUE)

Interactive Breakdown

Better Bets vs. Monte Rosa Therapeutics (GLUE)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

GLUE Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Diversification Alternatives

Repricing Catalyst

Industry Resources

Market Price (4/10/2026): $18.17 | Market Cap: $1.6 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (4/10/2026): $18.17
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology